From Russia (with love?) [RSABE / ABEL]

posted by PharmCat  – Russia, 2019-12-04 15:16 (684 d 18:06 ago) – Posting: # 20924
Views: 4,465

Hello Helmut!

IMHO, main points:

1. Basic words. Review article.
2. ABEL/RSABE - all have TIE inflation.
3. Biggest inflation when CVintra = 25—30%.
4. EMA aproach better than FDA.

Conclusion:

When you are planning bioequivalence trial better look at EMA guidelines, rather than FDA. We know that all approaches have TIE inflation.

I think this is primarily a message to regulatory experts.

Complete thread:

Activity
 Admin contact
21,738 posts in 4,546 threads, 1,543 registered users;
online 11 (0 registered, 11 guests [including 3 identified bots]).
Forum time: Tuesday 10:22 CEST (Europe/Vienna)

Sometimes the key to an answer is found
in the way you formulate the question.    David Brin

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5